Paul F. Pinsky, PhD; David S. Gierada, MD; William Hocking, MD; Edward F. Patz, Jr., MD; Barnett S. Kramer, MD, MPH
Grant Support: By the National Institutes of Health (U01-CA-80098, U01-CA-79778, N01-CN-25522, N01-CN-25511, N01-CN-25512, N01-CN-25513, N01-CN-25514, N01-CN-25515, N01-CN-25516, N01-CN-25518, N01-CN-25524, N01-CN-75022, N01-CN-25476, and N02-CN-63300).
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-1484.
Reproducible Research Statement:Study protocol and statistical code: Available from Dr. Pinsky (e-mail, email@example.com). Data set: Available upon request at https://biometry.nci.nih.gov/cdas.
Requests for Single Reprints: Paul F. Pinsky, PhD, National Cancer Institute, 9609 Medical Center Drive, Room 5E108, Bethesda, MD 20892.
Current Author Addresses: Drs. Pinsky and Kramer: National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD 20892.
Dr. Gierada: Washington University School of Medicine, 510 South Kingshighway Boulevard, St. Louis, MO 63110.
Dr. Hocking: Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI 54449.
Dr. Patz: Duke University School of Medicine, 1515B Hosp North, Durham, NC 27710.
Author Contributions: Conception and design: P.F. Pinsky, D.S. Gierada, E.F. Patz.
Analysis and interpretation of the data: P.F. Pinsky, D.S. Gierada, W. Hocking, E.F. Patz, B.S. Kramer.
Drafting of the article: P.F. Pinsky, W. Hocking, E.F. Patz.
Critical revision of the article for important intellectual content: P.F. Pinsky, D.S. Gierada, W. Hocking, E.F. Patz, B.S. Kramer.
Final approval of the article: P.F. Pinsky, D.S. Gierada, W. Hocking, E.F. Patz, B.S. Kramer.
Provision of study materials or patients: W. Hocking.
Statistical expertise: P.F. Pinsky.
Obtaining of funding: W. Hocking.
Collection and assembly of data: D.S. Gierada, W. Hocking.
Pinsky PF, Gierada DS, Hocking W, Patz EF, Kramer BS. National Lung Screening Trial Findings by Age: Medicare-Eligible Versus Under-65 Population. Ann Intern Med. 2014;161:627-633. doi: 10.7326/M14-1484
Download citation file:
Published: Ann Intern Med. 2014;161(9):627-633.
The NLST (National Lung Screening Trial) showed reduced lung cancer mortality in high-risk participants (smoking history of ≥30 pack-years) aged 55 to 74 years who were randomly assigned to screening with low-dose computed tomography (LDCT) versus those assigned to chest radiography. An advisory panel recently expressed reservations about Medicare coverage of LDCT screening because of concerns about performance in the Medicare-aged population, which accounted for only 25% of the NLST participants.
To examine the results of the NLST LDCT group by age (Medicare-eligible vs. <65 years).
Secondary analysis of a group from a randomized trial (NCT00047385).
33 U.S. screening centers.
19 612 participants aged 55 to 64 years (under-65 cohort) and 7110 participants aged 65 to 74 years (65+ cohort) at randomization.
3 annual rounds of LDCT screening.
Demographics, smoking and medical history, screening examination adherence and results, diagnostic follow-up procedures and complications, lung cancer diagnoses, treatment, survival, and mortality.
The aggregate false-positive rate was higher in the 65+ cohort than in the under-65 cohort (27.7% vs. 22.0%; P < 0.001). Invasive diagnostic procedures after false-positive screening results were modestly more frequent in the older cohort (3.3% vs. 2.7%; P = 0.039). Complications from invasive procedures were low in both groups (9.8% in the under-65 cohort vs. 8.5% in the 65+ cohort). Prevalence and positive predictive value (PPV) were higher in the 65+ cohort (PPV, 4.9% vs. 3.0%). Resection rates for screen-detected cancer were similar (75.6% in the under-65 cohort vs. 73.2% in the 65+ cohort). Five-year all-cause survival was lower in the 65+ cohort (55.1% vs. 64.1%; P = 0.018).
The oldest screened patient was aged 76 years.
NLST participants aged 65 years or older had a higher rate of false-positive screening results than those younger than 65 years but a higher cancer prevalence and PPV. Screen-detected cancer was treated similarly in the groups.
National Institutes of Health.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Pulmonary/Critical Care, Healthcare Delivery and Policy, Lung Cancer, Cancer Screening/Prevention.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only